First, the high expression of lncRNA CDKN2B-AS1 could accelerate the development of HCC regulating the PI3K/AKT/mTOR signaling pathway in which NAP1L1 was a target of lncRNA CDKN2B-AS1 (Huang et al., 2018). Here, CDKN2B is linked to hepatocellular carcinoma.